Table 2.
Qualitative results of antibody and T-cell induction after the second vaccination.
| 1° vaccine | NVX-CoV2373 | BNT162b2 | mRNA-1273 | |
|---|---|---|---|---|
| 2° vaccine | NVX-CoV2373 | BNT162b2 | mRNA-1273 | |
| n (% positive) | n = 22 | n = 22 | n = 22 | p-value |
| IgG (≥35.2 BAU/ml) | 22 (100%) | 22 (100%) | 22 (100%) | p = 1.00 |
| Neutralizing activity | ||||
| Parental (IH≥35%)1 | 22 (100%) | 22 (100%) | 22 (100%) | p = 1.00 |
| Delta (>0%)2 | 17 (77.3%) | 21 (95.5%) | 21 (95.5%) | p = 0.07 |
| BA.1 (>0%)2 | 1 (4.5%) | 0 (0%) | 4 (18.2%) | p = 0.06 |
| BA.2 (>0%)2,3 | 8 (36.4%) | 4 (25%)1 | 11 (50.0%) | p = 0.29 |
| CD4 T-cells (≥0.03%) | 18 (81.8%) | 22 (100%) | 22 (100%) | p = 0.01 |
| CD8 T-cells (≥0.03%) | 3 (13.6%) | 14 (63.6%) | 17 (77.3%) | p<0.0001 |
1
determined by a surrogate assay.
2
determined by a micro-neutralization assay.
3
BA.2 testing only available for n = 16 individuals. Shown is the number (percentage) of individuals with specific immune responses above the respective detection limit.